Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
Marios Georgakis, Research Group Leader and Physician at LMU Munich, Visiting Scientist at Broad Institute of MIT and Harvard University, shared on LinkedIn:
”In another win for genetically validated drug targets, a small molecule factor XI inhibitor on top of antiplatelet treatment, led to significant reductions (HR: 0.74, 95%CI: 0.65–0.84) in risk of recurrent ischemic stroke among patients with a non-cardioembolic ischemic stroke or TIA in the placebo-controlled OCEANIC-STROKE trial (12,327 patients).
As predicted by Mendelian randomization analyses several years ago, the benefit against ischemic stroke was not accompanied by an increase in risk of major bleeding, intracranial bleeding, or even minor bleeding.
This is unprecedented for an antithrombotic therapy.
Also interestingly, human genetic analyses had long supported no effects on myocardial infarction or coronary artery disease risk, which also lines up with the underwhelming available trial data in patients with acute myocardial infarction.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research
-
Jul 8, 2026, 19:25Luca Saba: Why Does the Same Patient Have Different Plaque in Different Arteries?
-
Jul 8, 2026, 19:25Luisa Weiss: Understanding the Molecular Differences Between Acute and Chronic Coronary Syndromes.